PharmaShots | Incisive News in 3 Shots

Subscribe Now

PD-L1

Chugai Launches Tecentriq Intravenous Infusion 840mg as an Optimal Formulation to Treat PD-L1+ Triple-Negative Breast Cancer in Japan

Chugai Launches Tecentriq Intravenous Infusion 840mg as an Optimal Formulation to Treat PD-L1+ Triple-Negative Breast Cancer in Ja...

November 28, 2019

BMS Reports Update of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -915 Study for Patients with Resected High-Risk Melanoma and PD-L1

BMS Reports Update of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -915 Study for Patients with Resected High-Risk...

November 20, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us